25 September 2026
Ending federal funds for a child brain cancer network set back an mRNA drug trial by a year
After the National Cancer Institute stopped funding a pediatric brain tumor consortium, researchers say a trial of an mRNA treatment for a deadly childhood cancer was delayed by at least a year.
DIPG is a brain tumor that mostly strikes children. It grows in the brainstem, where surgeons cannot operate, and only about 2% of patients survive five years. About 300 US children are diagnosed each year. A CNBC report shows how a change in federal research funding slowed work on one of the more hopeful new treatments.
What happened
In August 2025 the National Cancer Institute (NCI), part of the National Institutes of Health, told the Pediatric Brain Tumor Consortium it could no longer reapply for funding. The consortium, set up by NCI in 1999 and funded mostly by the federal government, is a network of hospitals and universities that runs trials for children with brain cancer. It came during a broader review of NIH grants led by the Department of Government Efficiency, or DOGE: between February and August 2025, more than $2 billion of research funding was withdrawn or frozen.
Researchers at Children's National Hospital and the University of Florida were preparing a trial of an mRNA treatment (the technology behind Covid vaccines) that trains a child's immune system to attack the tumor. Lead researcher Eugene Hwang told CNBC the loss of the consortium delayed the trial by at least a year. The consortium's chair, Ira Dunkel, said two trials were shut down, four are moving to a larger network, and no new patients could enroll for 13 months.
The Department of Health and Human Services disagrees that treatments were delayed. A spokeswoman said NCI is moving the trials to a larger network to speed up progress, and that "this decision was not a cost-cutting measure."
CNBC's report centers on a young boy with DIPG whose family had hoped he could join the trial. His cancer has since spread, making him ineligible, and he is now in hospice care.
Why it matters
Medical research is a pipeline: government grants pay for early studies, and drug companies often build on them. Childhood cancer gets only about 4% of federal cancer research money, and most funding for children's brain tumor research comes from foundations started by parents who lost a child to the disease. When the federal piece shrinks, there is little to fill the gap quickly. mRNA has shown promise elsewhere: in August, Merck and Moderna reported positive late-stage results for an mRNA-based melanoma treatment.
What to watch
- Whether the team secures money from the Pediatric Neuro-Oncology Consortium or a new NIH grant.
- The White House's reported retreat from an order that would have let it block some NIH grants.
- When the mRNA trial actually opens to patients.
Based on reporting by CNBC: NIH cuts delayed a cancer trial. Patients lost time they didn't have. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion